Michel Sadelain

Michel Sadelain
Name	Michel Sadelain
Birth date	1959
Birth place	Paris, France
Nationality	French-American
Fields	Immunology, Oncology, Hematology
Workplaces	Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Recombinant DNA Advisory Committee, Shanahan Research Institute
Alma mater	University of Paris, Paris-Sud University, Institut Pasteur
Known for	Chimeric antigen receptor CAR T cell therapy
Awards	Dannie Heineman Prize for Mathematical Physics, AACR-Princess Takamatsu Award, National Academy of Sciences

Michel Sadelain is a physician-scientist and immunologist noted for pioneering work in cellular immunotherapy and genetically engineered lymphocytes. He is associated with leading cancer and biomedical research institutions and has shaped translational approaches that link basic science from laboratories such as Institut Pasteur and Cold Spring Harbor Laboratory to clinical programs at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine. His work intersects with major figures and organizations across oncology, hematology, and biotechnology.

Early life and education

Born in Paris, Sadelain trained in medicine and basic science at prominent French institutions including University of Paris and Paris-Sud University, with formative experiences at Institut Pasteur. He pursued advanced research that connected to programs at Pasteur Institute, INSERM, and collaborations reaching Harvard Medical School and Massachusetts Institute of Technology, embedding him within networks that include André Lwoff, Françoise Barré-Sinoussi, and laboratories linked to Jean Dausset and Luc Montagnier. His education combined clinical training relevant to Hôpital Necker–Enfants Malades and research exposure paralleling groups at Cold Spring Harbor Laboratory and Salk Institute.

Career and research

Sadelain established a laboratory focused on genetic engineering of lymphocytes within Memorial Sloan Kettering Cancer Center and served on faculty at Weill Cornell Medicine, interacting with translational programs allied to Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, and regulatory frameworks like the FDA and advisory bodies such as the Recombinant DNA Advisory Committee. His team collaborated with biotechnology firms and academic partners including Novartis, Kite Pharma, Bluebird Bio, Juno Therapeutics, Seattle Children’s Hospital, and international centers like University College London and University of Toronto. Research topics spanned engineered receptors, T cell signaling, adoptive cell transfer, tumor microenvironment studies connected to work at Broad Institute and NYU Langone Health. His network included interactions with scientists such as Carl June, James Allison, Toni Ribas, Steven Rosenberg, and Michel A. Nussenzweig.

Chimeric antigen receptor (CAR) T-cell therapy

Sadelain’s laboratory contributed foundational advances in designing chimeric antigen receptors, development that connected to antigen targets like CD19, CD20, BCMA, and strategies related to PD-1 blockade and combination regimens involving agents from Bristol-Myers Squibb, Merck, and Roche. He advanced concepts of co-stimulatory domains derived from CD28 and 4-1BB and addressed challenges seen in clinical contexts at centers including Johns Hopkins Hospital, Mayo Clinic, UCLA Medical Center, and Stanford Health Care. Work integrated preclinical models from collaborations with groups at Yale School of Medicine, University of Pennsylvania, and Fred Hutchinson Cancer Center, informing trials registered with oversight by National Institutes of Health and ethics boards at institutions like Columbia University Irving Medical Center.

Key publications and contributions

Sadelain authored and co-authored influential papers that shaped practice and policy, appearing alongside contributors from Nature, Science, The New England Journal of Medicine, and Blood. His publications addressed CAR design, vector systems using lentiviral and gamma-retroviral platforms, safety switches, antigen escape, and manufacturing approaches tied to cell processing at facilities like Cellectis and Lonza. His work intersected with methodological advances from George Church, Feng Zhang, Jennifer Doudna, Emmanuelle Charpentier, and clinical trial frameworks exemplified by groups at Memorial Sloan Kettering Cancer Center, University of Pennsylvania, and Fred Hutchinson Cancer Center.

Awards and honors

Sadelain’s recognitions include election to bodies and receipt of awards connected to National Academy of Medicine, National Academy of Sciences, and honors presented by societies such as the American Association for Cancer Research, American Society of Hematology, and American Society of Clinical Oncology. He has received prizes and lectureships alongside honorees like James P. Allison, Tasuku Honjo, Carl June, and institutions including Cold Spring Harbor Laboratory and Karolinska Institutet that highlight his impact on cancer immunotherapy and translational science.

Personal life and legacy

Sadelain’s legacy is reflected in translational programs, spinout companies, and trainees who have joined faculties across institutions such as UCSF School of Medicine, University of California, San Diego, Imperial College London, and University of Oxford. His mentoring influenced clinicians and scientists operating within networks spanning WHO, European Medicines Agency, and national research agencies like NIH and INSERM. The clinical application of his work continues to shape standards at hospitals including Mount Sinai, Cleveland Clinic, and global cancer centers, linking his contributions to ongoing developments in engineered cellular therapies and immuno-oncology.

Category:Immunologists Category:Hematologists